News

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025. ASCO 2025 overall survival data bolster IMNN-001’s ...
Potential Positives. IMUNON secured approximately $3.25 million in net proceeds from a successful private placement of common stock and short-term warrants, strengthening its financial position.
Imunon formally requested to retract its Form S-1 registration with the SEC after initially registering the document on April 4. The biotech firm's shares rose 4.1% to $0.42 on Thursday and sur ...
IMUNON, Inc. has initiated the first trial site for its Phase 3 OVATION 3 study of IMNN-001, a DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer, following successful results ...
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.
Imunon’s stock skyrocketed on massive volume Tuesday, after the biotechnology company announced positive survival data from a trial of its ovarian cancer treatment, IMNN-001.
LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with ...
Imunon’s stock skyrocketed on massive volume Tuesday, after the biotechnology company announced positive survival data from a trial of its ovarian cancer treatment, IMNN-001.
LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 ...